These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11990864)

  • 41. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
    Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
    J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
    Moreland LW; Weinblatt ME; Keystone EC; Kremer JM; Martin RW; Schiff MH; Whitmore JB; White BW
    J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.
    Prince FH; Twilt M; Simon SC; van Rossum MA; Armbrust W; Hoppenreijs EP; Kamphuis S; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; ten Cate R; van Suijlekom-Smit LW
    Ann Rheum Dis; 2009 Jul; 68(7):1228-9. PubMed ID: 19525408
    [No Abstract]   [Full Text] [Related]  

  • 44. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.
    Schotte H; Schlüter B; Willeke P; Mickholz E; Schorat MA; Domschke W; Gaubitz M
    Rheumatology (Oxford); 2004 Aug; 43(8):960-4. PubMed ID: 15026584
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept.
    McMinn JR; Cohen S; Moore J; Lilly S; Parkhurst J; Tarantino MD; Terrell DR; George JN
    Am J Hematol; 2003 Jun; 73(2):135-40. PubMed ID: 12749017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis.
    Hall SJ; Hickling P
    J Clin Rheumatol; 2007 Feb; 13(1):54. PubMed ID: 17278957
    [No Abstract]   [Full Text] [Related]  

  • 48. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept).
    Sinha A; Patient C
    J Obstet Gynaecol; 2006 Oct; 26(7):689-91. PubMed ID: 17071443
    [No Abstract]   [Full Text] [Related]  

  • 49. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis.
    Yelin E; Trupin L; Katz P; Lubeck D; Rush S; Wanke L
    Arthritis Rheum; 2003 Nov; 48(11):3046-54. PubMed ID: 14613265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?
    Reinders MK; van Roon EN; Brouwers JR; Jansen TL
    Ann Rheum Dis; 2005 Mar; 64(3):516; author reply 516. PubMed ID: 15708917
    [No Abstract]   [Full Text] [Related]  

  • 51. Formularies at the touch of a pad. Firms offer doctors access to right drugs, referral options on palmtop computers.
    Morrissey J
    Mod Healthc; 1999 Sep; 29(37):22, 24. PubMed ID: 10621395
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of managed care on oncology.
    Valadez AM; Sportsman S
    Semin Oncol Nurs; 2002 May; 18(2):149-53. PubMed ID: 12051167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Formularies and therapeutic interchange in managed care.
    Dillon MJ
    Am J Health Syst Pharm; 1999 Sep; 56(17):1776; author reply 1777. PubMed ID: 10512515
    [No Abstract]   [Full Text] [Related]  

  • 54. Battles over turf persist in managed-care era.
    Linton OW
    Diagn Imaging (San Franc); 1996 Nov; 18(11):59-61, 63, 65. PubMed ID: 10163647
    [No Abstract]   [Full Text] [Related]  

  • 55. New managed-care glossary.
    Grimaldi PL
    Nurs Manage; 1999 Nov; 30(11):16-20. PubMed ID: 10765264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stretchers.
    Needham CW
    Conn Med; 2001 Oct; 65(10):607-9. PubMed ID: 11702520
    [No Abstract]   [Full Text] [Related]  

  • 57. Forum on managed care controls?
    Berman LH
    Conn Med; 2001 Feb; 65(2):122. PubMed ID: 11265601
    [No Abstract]   [Full Text] [Related]  

  • 58. Ethics and managed care formularies.
    Swartwood DE
    Am J Health Syst Pharm; 2000 May; 57(9):851. PubMed ID: 10840525
    [No Abstract]   [Full Text] [Related]  

  • 59. Etanercept and its implications for managed care.
    Lipsy RJ
    Am J Manag Care; 2002 Apr; 8(6 Suppl):S194-200. PubMed ID: 11990864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case study on rheumatoid arthritis.
    Baker T
    Am J Manag Care; 2003 Sep; 9(4 Suppl):S87-98. PubMed ID: 14527109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.